Galectin Therapeutics Inc. (GALT)
- Previous Close
3.0600 - Open
2.9900 - Bid 2.3400 x 200
- Ask 3.8400 x 200
- Day's Range
2.9900 - 3.2993 - 52 Week Range
1.2800 - 4.2700 - Volume
61,442 - Avg. Volume
146,708 - Market Cap (intraday)
203.044M - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7400 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
galectintherapeutics.comRecent News: GALT
Performance Overview: GALT
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GALT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GALT
Valuation Measures
Market Cap
188.19M
Enterprise Value
236.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-6.19
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-96.17%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-44.8M
Diluted EPS (ttm)
-0.7400
Balance Sheet and Cash Flow
Total Cash (mrq)
25.66M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-20.68M